Engineered Vesicles Delivered Therapeutic RNA to Cells
Researchers developed a delivery method using platelet-derived vesicles to target protein pathways implicated in schizophrenia.
Updated on Sept. 23, 2026 in Life Sciences
Scientists have engineered platelet-derived extracellular vesicles to transport miR-320a directly into SH-SY5Y cells. This research-stage study demonstrates that the delivered molecules successfully modulate cellular pathways by targeting specific proteins.
Why it matters
Platelet-derived extracellular vesicles are considered promising drug delivery vehicles due to their natural abundance and ability to cross the blood-brain barrier. Identifying the miR-320a/ITGβ1 pathway provides a potential new therapeutic axis for addressing schizophrenia.
The study utilized electroporation to load miR-320a into platelet-derived extracellular vesicles, which subsequently downregulated ITGβ1 proteins. This mechanism increased SH-SY5Y cell viability and enhanced retinoic acid-induced neuronal differentiation compared to untreated cells.
The players
SH-SY5Y cells
A standardized human-derived cell line frequently utilized in neuroscience research to model neuronal function and differentiation.
The details
Researchers employed electroporation — a technique that uses electrical pulses to create temporary pores in cell membranes — to encapsulate miR-320a into platelet-derived extracellular vesicles, or PEVs. These PEVs, naturally occurring membrane-bound particles, were then internalized by the SH-SY5Y cell line, a widely used model for human nerve cells. Once inside, the miR-320a downregulated integrin β1, a transmembrane protein involved in cell signaling. This regulation increased both cell viability and dopamine levels in cells undergoing neuronal differentiation.
Timeline
September 23, 2026: Article published online.
The Tech Race
This study advances the competitive race to develop non-viral, bio-compatible delivery systems capable of traversing the blood-brain barrier. It follows a broader trend in synthetic biology that prioritizes the use of naturally occurring extracellular vesicles over traditional synthetic liposomes for central nervous system targets.
This development is currently limited to laboratory-stage research and has no immediate application for patients or clinicians. Future progress will depend on successfully replicating these results in animal models and clinical trials to determine the stability and safety of the delivery method.
The takeaway
This finding highlights a potential method for targeted RNA delivery into neural cells by leveraging blood-derived vesicles. Future studies should be monitored for results in animal models to determine if the miR-320a/ITGβ1 pathway can be validated as a viable therapeutic target for schizophrenia.
Further reading
For more research on emerging therapeutic delivery mechanisms, see Life Sciences.
Source note: This article includes information reported by Nature.
